Erschienen in:
28.09.2018 | Systemic Therapies in Colorectal Cancer (RD Kim, Section Editor)
Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer
verfasst von:
Dae Won Kim, Jung-Hoon Lee, Kunhwa Kim, Iman Imanirad
Erschienen in:
Current Colorectal Cancer Reports
|
Ausgabe 6/2018
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
This review examines the pathophysiological features of microsatellite instability (MSI) high colorectal cancer and discusses recent clinical studies of immune checkpoint inhibitors for MSI high colorectal cancer.
Recent Findings
Emerging clinical data demonstrated durable clinical activity and safety of PD-1 blockade agents in diverse cancers, and PD-1 blockade agents have led to a paradigm shift in the cancer therapy. Although initial clinical data showed disappointing result of anti-PD-1 therapy in unselected metastatic colorectal cancer, recent data demonstrated promising results with significant anticancer activity of PD-1 blockade in colorectal cancers with microsatellite instability which have highly immunogenic tumor microenvironment.
Summary
Anti-PD-1 therapy demonstrated durable clinical activity and safety, and it has changed the landscape of cancer therapy in MSI high colorectal cancer. Further studies with better understanding of tumor microenvironment will improve clinical outcomes of colorectal cancer.